MX2007004934A - Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina. - Google Patents
Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina.Info
- Publication number
- MX2007004934A MX2007004934A MX2007004934A MX2007004934A MX2007004934A MX 2007004934 A MX2007004934 A MX 2007004934A MX 2007004934 A MX2007004934 A MX 2007004934A MX 2007004934 A MX2007004934 A MX 2007004934A MX 2007004934 A MX2007004934 A MX 2007004934A
- Authority
- MX
- Mexico
- Prior art keywords
- dpp
- combination
- conditions
- treatment
- progression
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title abstract 2
- 101150014691 PPARA gene Proteins 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 5
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 abstract 1
- 208000010444 Acidosis Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000007976 Ketosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010027417 Metabolic acidosis Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000004140 ketosis Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a una combinacion, tal como a una preparacion combinada o a una composicion farmaceutica, respectivamente, la cual comprende: (1) un inhibidor de dipeptidil-peptidasa IV (DPP-IV), (2) un anti-diabetico seleccionado a partir de tiazolidinadionas (gitazonas), agonistas de PPAR( que no son de tipo glitazona, agonistas de PPAR(, o agonistas dobles de PPAR(/ PPAR(, y (3) metformina, para su uso simultaneo, separado, o en secuencia, en especial en la prevencion, demora de progreso, o tratamiento de las condiciones mediadas por la dipeptidil-peptidasa IV (DPP-IV), en particular diabetes, mas particularmente diabetes mellitus tipo 2, condiciones de tolerancia deteriorada a la glucosa (IGT), condiciones de glucosa deteriorada en plasma en ayunas, acidosis metabolica, cetosis, artritis, obesidad, y osteroporosis; al uso de esta combinacion para la preparacion de una preparacion farmaceutica para la prevencion, demora de progreso, o tratamiento de estas condiciones; al uso de esta combinacion para el tratamiento cosmetico de un mamifero con el objeto de efectuar una perdida cosmeticamente benefica del peso corporal; a un metodo para la prevencion, demora de progreso, o tratamiento de las condiciones mediadas por la dipeptidil-peptidasa IV; y a un metodo para mejorar la apariencia corporal de un animal de sangre caliente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62189104P | 2004-10-25 | 2004-10-25 | |
| PCT/US2005/037819 WO2006047248A1 (en) | 2004-10-25 | 2005-10-21 | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004934A true MX2007004934A (es) | 2007-06-12 |
Family
ID=35717718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004934A MX2007004934A (es) | 2004-10-25 | 2005-10-21 | Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090253752A1 (es) |
| EP (1) | EP1807066A1 (es) |
| JP (1) | JP2008517921A (es) |
| KR (1) | KR20070068407A (es) |
| CN (1) | CN101035522B (es) |
| AU (2) | AU2005299808B2 (es) |
| BR (1) | BRPI0518409A2 (es) |
| CA (1) | CA2581298A1 (es) |
| MX (1) | MX2007004934A (es) |
| RU (1) | RU2007119320A (es) |
| WO (1) | WO2006047248A1 (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| HRP20140091T4 (hr) * | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
| WO2007035665A1 (en) * | 2005-09-20 | 2007-03-29 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| AU2011202574B2 (en) * | 2005-09-20 | 2012-02-02 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
| JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
| JP2009522374A (ja) * | 2006-01-06 | 2009-06-11 | ノバルティス アクチエンゲゼルシャフト | 糖尿病処置のためのビルダグリプチンの使用 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| JP2010508348A (ja) * | 2006-11-01 | 2010-03-18 | ノバルティス アーゲー | 浮腫の予防、遅延または軽減のためのジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| UA95828C2 (ru) | 2007-02-01 | 2011-09-12 | Такеда Фармасьютикал Компани Лимитед | Твердая рецептура, которая содержит алоглиптин и пиоглитазон |
| EP2139464A1 (en) * | 2007-03-15 | 2010-01-06 | Nectid, Inc. | Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| CA2713361A1 (en) * | 2008-02-05 | 2009-08-13 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
| MX2011006713A (es) | 2008-12-23 | 2011-07-13 | Boehringer Ingelheim Int | Formas salinas de compuesto organico. |
| WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| JP2012517977A (ja) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
| EP2408434A4 (en) * | 2009-03-16 | 2013-11-27 | Ipintl Llc | TREATMENT OF MORBUS ALZHEINER AND OSTEOPOROSE AND REDUCTION OF AGING |
| JP5734981B2 (ja) | 2009-09-02 | 2015-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン |
| NZ598685A (en) | 2009-09-11 | 2013-05-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| WO2011037793A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| EP2490534A4 (en) * | 2009-10-23 | 2013-06-12 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE |
| SMT201800495T1 (it) * | 2009-11-13 | 2018-11-09 | Astrazeneca Ab | Formulazioni di compresse a doppio strato |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| EP2356985A1 (en) * | 2010-02-10 | 2011-08-17 | LEK Pharmaceuticals d.d. | Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| US20120107398A1 (en) * | 2010-05-05 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
| WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| TR201010683A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
| WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| BR112014010228B1 (pt) | 2011-10-28 | 2020-09-29 | Lumena Pharmaceuticals Llc | Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849754B1 (en) | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| CN106706768B (zh) * | 2015-11-17 | 2021-05-11 | 重庆医药工业研究院有限责任公司 | 一种分离测定恩格列净及其有关物质的方法 |
| JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US11103469B2 (en) | 2019-09-17 | 2021-08-31 | Novartis Ag | Combination therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| PT1741445E (pt) * | 2000-01-21 | 2013-11-11 | Novartis Ag | Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
-
2005
- 2005-10-21 MX MX2007004934A patent/MX2007004934A/es unknown
- 2005-10-21 AU AU2005299808A patent/AU2005299808B2/en not_active Ceased
- 2005-10-21 KR KR1020077009270A patent/KR20070068407A/ko not_active Ceased
- 2005-10-21 WO PCT/US2005/037819 patent/WO2006047248A1/en not_active Ceased
- 2005-10-21 RU RU2007119320/15A patent/RU2007119320A/ru unknown
- 2005-10-21 US US11/577,941 patent/US20090253752A1/en not_active Abandoned
- 2005-10-21 EP EP05816082A patent/EP1807066A1/en not_active Withdrawn
- 2005-10-21 JP JP2007538049A patent/JP2008517921A/ja active Pending
- 2005-10-21 CN CN2005800343814A patent/CN101035522B/zh not_active Expired - Fee Related
- 2005-10-21 BR BRPI0518409-6A patent/BRPI0518409A2/pt not_active IP Right Cessation
- 2005-10-21 CA CA002581298A patent/CA2581298A1/en not_active Abandoned
-
2009
- 2009-10-01 AU AU2009222515A patent/AU2009222515A1/en not_active Abandoned
-
2011
- 2011-08-15 US US13/209,890 patent/US20110301172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101035522A (zh) | 2007-09-12 |
| KR20070068407A (ko) | 2007-06-29 |
| AU2005299808B2 (en) | 2009-08-20 |
| RU2007119320A (ru) | 2008-11-27 |
| WO2006047248A1 (en) | 2006-05-04 |
| AU2009222515A1 (en) | 2009-10-22 |
| US20110301172A1 (en) | 2011-12-08 |
| CN101035522B (zh) | 2011-12-07 |
| AU2005299808A1 (en) | 2006-05-04 |
| CA2581298A1 (en) | 2006-05-04 |
| EP1807066A1 (en) | 2007-07-18 |
| US20090253752A1 (en) | 2009-10-08 |
| BRPI0518409A2 (pt) | 2008-11-18 |
| JP2008517921A (ja) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007004934A (es) | Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina. | |
| WO2001052825A3 (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| WO2006039325A3 (en) | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2006127530A3 (en) | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| PT1572196E (pt) | Combinação de um inibidor da dpp-iv e um composto ppar alfa | |
| TW200504063A (en) | DPP-IV inhibitors | |
| WO2006023750A3 (en) | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| BRPI0411726A (pt) | composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino | |
| WO2005011581A3 (en) | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| NZ594487A (en) | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof | |
| WO2006058064A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2003000180A3 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
| WO2008017670A8 (en) | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus | |
| WO2004048345A3 (en) | 2,5-diketopiperazines for the treatment of obesity | |
| TNSN05320A1 (en) | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors | |
| YU74102A (sh) | Malonaminske kiseline i njihovi derivati kao ligandi tireoidnog receptora | |
| MXPA04003759A (es) | Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv. | |
| WO2007017145A3 (en) | Gsk-3 inhibitors | |
| WO2006058628A3 (en) | Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes | |
| WO2006047470A3 (en) | Compositions containing malva sylvestris extract and use thereof on skin or mucosal tissues | |
| WO2005114206A3 (en) | Diagnostics and therapeutics for diseases associated with serotonin 5-ht5a receptor (5ht5a) | |
| WO2004044229A3 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2) | |
| WO2006013015A3 (en) | Diagnostics and therapeutics for diseases associated with marapsin (mpn) |